Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rezolute Inc
(NQ:
RZLT
)
2.700
+0.060 (+2.27%)
Streaming Delayed Price
Updated: 11:39 AM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
111,923
Open
2.640
Bid (Size)
2.750 (10)
Ask (Size)
2.850 (1)
Prev. Close
2.640
Today's Range
2.640 - 2.850
52wk Range
0.7200 - 3.690
Shares Outstanding
40,135,147
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024
May 15, 2024
RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
May 15, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Performance
YTD
+166.01%
+166.01%
1 Month
-21.28%
-21.28%
3 Month
+86.21%
+86.21%
6 Month
+259.95%
+259.95%
1 Year
+31.71%
+31.71%
More News
Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 23, 2024
Via
Benzinga
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
April 15, 2024
Via
Investor Brand Network
Analyst Expectations for Rezolute's Future
November 14, 2023
Via
Benzinga
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
April 15, 2024
Via
InvestorPlace
CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
April 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Stocks Insiders Are Buying That Analysts Love
March 26, 2024
Via
MarketBeat
$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
March 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
March 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
March 06, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying
February 28, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
February 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rezolute And 3 Other Penny Stocks Insiders Are Buying
February 21, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
December 20, 2023
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
November 24, 2023
Via
Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
November 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 11, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.